AB008. Final analysis from PECATI phase 2 trial: lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
Background There is no standard second-line treatment for patients with platinum refractory advanced B3-Thymoma (T) and thymic carcinoma (TC). In this population, the PECATI trial testing lenvatinib plus pembrolizumab met its primary endpoint, with 5-month progression-free survival (PFS) of 88.0% (90% CI: 73.5–94.8). M...